Reality Check on Multiple Sclerosis
Market access for multiple sclerosis treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.
To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:
- Payer Insights: Under the pharmacy benefit, about 62% of the lives under commercial formularies are covered with utilization management restrictions
- Class Trends: In December 2020, the FDA approved a new dosing time for Roche Group unit Genentech USA, Inc.’s Ocrevus (ocrelizumab) to treat adults with relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, as well as primary progressive MS. Twice-yearly dosing via a shorter two-hour infusion is now available for people who have not experienced any serious infusion reactions
- Key Findings: Interferons and Copaxone, as well as its generics, are considered first line in the treatment pathway. There are no true generics for the interferons. But with Copaxone generics, including Glatopa (glatiramer acetate), available, some plans require those to be used
What can pharma do to curb this trend and overcome these challenges?
Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.
Download the full Reality Check now.